A practical reference on Albumin conjugation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-03. Anything still debated is marked as such rather than presented as settled.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Nalbuphine HCL is currently available only as an injectable in the US and the European Union. Nubain, the Astra USA brand name for injectable nalbuphine HCL, was discontinued from being marketed in 2008 in the United States for commercial reasons (Federal Register 2008); however, other commercial suppliers now provide generic injection formulation nalbuphine for the market.
MDDMA, or MDDM, also known as 3,4-methylenedioxy-N,N-dimethylamphetamine or as N,N-dimethyl-MDA or N-methyl-MDMA, is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families. It is the N,N-dimethyl analogue of MDA and the N-methyl derivative of MDMA. The drug is a known synthetic impurity of MDMA and has also been described as a possible novel designer drug in 2025. In addition, (R)-MDDMA was characterized as a non-hallucinogenic psychoplastogen with antidepressant-like effects and improved safety relative to MDMA in 2026.
24494Pu + 4820Ca → 292114* → 290114 + 2 n + e− → 290113 + νe ? A single atom was observed which was thought to be the isotope 289114: the results were published in January 1999. Despite numerous attempts to repeat this reaction, an isotope with these decay properties has never again been found, and the exact identity of this activity is unknown. A 2016 paper by Sigurd Hofmann et al. considered that the most likely explanation of the 1998 result is that two neutrons were emitted by the produced compound nucleus, leading to 290114 and electron capture to 290113, while more neutrons were emitted in all other produced chains. This would have been the first report of a decay chain from an isotope of element 113, but it was not recognised at the time, and the assignment is still uncertain. A similar long-lived activity observed by the JINR team in March 1999 in the 242Pu + 48Ca reaction may be due to the electron-capture daughter of 287114, 287113; this assignment is also tentative.
A Bitubale is baled asphalt, in cold form, wrapped in white plastic or in asphalt-based film. Invented by Singapore-based Eastern Petroleum Group, Bitubale is a green technology innovation for the global bitumen (asphalt) transport supply chain. Bitubales are produced in specially designed plants for cooling, dispensing, encapsulation, and packing of bitumen at its supply source. The technologies support cold-form transport of bitumen with zero waste at the end of its supply chain. Primary benefits of the Bitubale, over hot-form transported asphalt, are halving of the CO2 emissions across the bitumen transport supply chain, large increases in workplace safety for bitumen/asphalt transport workers, elimination of long-term health risks from bitumen/asphalt fumes for transportation workers, elimination of accidental pollution of environmental assets during asphalt transport, and elimination of polluting bitumen-residue waste in millions of discarded drums in landfills.
== Selected awards == US National Academy of Inventors, Elected Fellow, 2018 T. & A. Higuchi Memorial Lectureship Award, Academy of Pharmaceutical Science and Technology, Japan, 2018 Distinguished Mentor Award, University of Utah, 2017 Doctor of Philosophy honoris causa, University of Helsinki, Finland, 2014 US National Academy of Engineering, Member, 2011 Honorary professorship, Sichuan University, China, 2007 Distinguished International Scientist Award, Japanese Biomaterials Society, 2006 Chair, Gordon Research Conference on Drug Carriers in Medicine and Biology, 2004 J. Heyrovský Honorary Medal for Merit in the Chemical Sciences, Academy of Sciences of the Czech Republic, 2003 Paul Dawson Biotechnology Award, American Association of Colleges of Pharmacy, 2001 Millennial Pharmaceutical Scientist Award, Millennial World Congress of Pharm. Sciences, 2000 Fellow of Biomaterials Science and Engineering, International Union of Societies of Biomaterials Science and Engineering, 1999 Founders Award, Controlled Release Society, 1999 Czech Learned Society, Honorary Member, 1998 Award of the Presidia of the Czechoslovak and USSR Academies of Sciences 1977 Selected publications and patents
Sources: en.wikipedia.org
The first β-sheet structure was proposed by William Astbury in the 1930s. He proposed the idea of hydrogen bonding between the peptide bonds of parallel or antiparallel extended β-strands. However, Astbury did not have the necessary data on the bond geometry of the amino acids in order to build accurate models, especially since he did not then know that the peptide bond was planar. A refined version was proposed by Linus Pauling and Robert Corey in 1951. Their model incorporated the planarity of the peptide bond which they previously explained as resulting from keto-enol tautomerization.
A wide variety of neptunium sulfide compounds have been characterized, including the pure sulfide compounds NpS, NpS3, Np2S5, Np3S5, Np2S3, and Np3S4. Of these, Np2S3, prepared by reacting NpO2 with hydrogen sulfide and carbon disulfide at around 1000 °C, is the most well-studied and three allotropic forms are known. The α form exists up to around 1230 °C, the β up to 1530 °C, and the γ form, which can also exist as Np3S4, at higher temperatures. NpS can be produced by reacting Np2S3 and neptunium metal at 1600 °C and Np3S5 can be prepared by the decomposition of Np2S3 at 500 °C or by reacting sulfur and neptunium hydride at 650 °C. Np2S5 is made by heating a mixture of Np3S5 and pure sulfur to 500 °C. All of the neptunium sulfides except for the β and γ forms of Np2S3 are isostructural with the equivalent uranium sulfide and several, including NpS, α−Np2S3, and β−Np2S3 are also isostructural with the equivalent plutonium sulfide. The oxysulfides NpOS, Np4O4S3, and Np2O2S have also been produced, although the latter two have not been well studied. NpOS was first prepared in 1985 by vacuum sealing NpO2, Np3S5, and pure sulfur in a quartz tube and heating it to 900 °C for one week. Neptunium selenide compounds that have been reported include NpSe, NpSe3, Np2Se3, Np2Se5, Np3Se4, and Np3Se5. All of these have only been obtained by heating neptunium hydride and selenium metal to various temperatures in a vacuum for an extended period of time and Np2Se3 is only known to exist in the γ allotrope at relatively high temperatures.
==== Metal substitution ==== This strategy involves substitution of a native metal center in a metallocofactor, by another metal, that might or might not be already present in living systems. In this way, electronic and steric properties of the catalytic active site are altered compared to the wild-type enzyme, and novel catalytic pathways are unlocked.
Narrowly most residents included an owner-occupier in their household, with 23.17% of households owning their house outright, and a further 31.33% owning with a mortgage. 10.59% were in local authority housing, with a further 13.29% renting from a housing association, or other registered social landlord. The 2021 census found that the borough has England and Wales's lowest proportion of people born in the UK, at 43.9%. The borough of Brent is extremely ethnically diverse, having changed greatly since 1951. In the 2011 census, those who identified as White British made up 18% of the borough's population. 18% identified as other White, 5% were of mixed heritage, those of South Asian heritage comprised about 33%, those of African and Caribbean heritage about 19%, and other ethnic groups about 7%. White ethnicities were relatively high in the wards of Mapesbury (straddling Willesden Green and Cricklewood), Brondesbury Park, Queen's Park and Kilburn. Black ethnicities in highest proportion were in Stonebridge, Harlesden and Kensal Green wards. Asian ethnicities in highest proportion were in the wards of Alperton, Wembley Central and Kenton. Those who ethnically identify as BAME (Black, Asian and minority Ethnic) was as high as 86% in Wembley Central – one of the highest in London – and most other Brent wards have a majority BAME population. Queen's Park had the lowest BAME proportion, at 37.0%. Brent has the highest proportion of Irish residents in Britain, with 4% of the population.
Sources: en.wikipedia.org
Bauman Moscow State Technical University, founded in 1830, is located in the city center; the university educates 18,000 undergraduate and 1,000 postgraduate students in science and engineering, offering technical degrees.
In the Western hemisphere, tostones (also known as banann peze in Haiti, tachinos or chatinos in Cuba, and patacones in Colombia, Costa Rica, Ecuador, Honduras, Panama, Peru and Venezuela) are twice-fried plantain fritters, often served as a side dish, appetizer or snack. Plantains are sliced in 4 cm (2 in) long pieces and fried in oil. The segments are then removed and individually smashed down to about half their original height. Finally, the pieces are fried again and then seasoned, often with salt. In some countries, such as Cuba, Puerto Rico and the Dominican Republic, the tostones are dipped in Creole sauce from chicken, pork, beef, or shrimp before eating. In Haiti, bannann peze is commonly served with pikliz, a slaw-like condiment made with cabbage, onions, carrots and scotch bonnet peppers. In Nicaragua, tostones are typically served with fried cheese (Tostones con queso) and sometimes with refried beans. While the name tostones is used to describe this food when prepared at home, in some South American countries the word also describes plantain chips, which are typically purchased from a store. In western Venezuela, much of Colombia and the Peruvian Amazon, patacones are a frequently seen variation of tostones. Plantains are sliced in long pieces and fried in oil, then used to make sandwiches with pork, beef, chicken, vegetables and ketchup. They can be made with unripe patacon verde or ripe patacon amarillo plantains.
=== Tissue transglutaminase === Tissue transglutaminase modifies gluten peptides into a form that may stimulate the immune system more effectively. These peptides are modified by tTG in two ways, deamidation or transamidation.
== See also == Dark cell Epithelial-mesenchymal transition Epithelial polarity Glycocalyx Inner and outer enamel epithelium Iris pigment epithelium Neuroepithelial cell Retinal pigment epithelium Skin cancer Sulcular epithelium List of distinct cell types in the adult human body
The reference values vary across studies, ranging from > 25 cm/s to > 35 cm/s. Values above 35 cm/s indicate the absence of arterial disease, values below 25 cm/s indicate arterial insufficiency, and values of 25–35 cm/s are indeterminate because they are less specific (see image below). The data obtained should be correlated with the degree of erection observed. If the peak systolic velocities are normal, the final diastolic velocities should be evaluated, those above 5 cm/s being associated with venogenic ED.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.